⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EVAX News
Evaxion A/S American Depositary Share
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
globenewswire.com
EVAX
Evaxion announces business update and third quarter 2025 financial results
globenewswire.com
EVAX
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
globenewswire.com
EVAX
Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
globenewswire.com
EVAX
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
globenewswire.com
EVAX
Evaxion raises $7.2 million, extending cash runway to second half of 2027
globenewswire.com
EVAX
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
globenewswire.com
EVAX
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
prnewswire.com
GTBP
EVAX
RNXT
EDAP
XNCR
GTBP
EVAX
RNXT
EDAP
XNCR
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
globenewswire.com
EVAX
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
globenewswire.com
EVAX